FDA News

FDA grants breakthrough therapy designation to Keytruda-Lenvima combination for hepatocellular carcinoma

July 23, 2019
The FDA granted breakthrough therapy designation to pembrolizumab in combination with lenvatinib as first-line treatment for patients with advanced…

Seven important updates in immuno-oncology

July 19, 2019
Healio.com and HemOnc Today provide a compilation of seven important updates in immuno-oncology from the past month.
Meeting News

Nonengineered T-cells may be ‘clinically meaningful’ for pancreatic cancer

July 19, 2019
More than half of patients with pancreatic adenocarcinoma showed clinical responses when treated with an investigational multiantigen-specific T-cell…
Feature

Intersection of radiotherapy, immunotherapy guides Penn’s new cancer research center

July 18, 2019
The Abramson Cancer Center at the University of Pennsylvania has been awarded a $12 million grant from the Mark Foundation for Cancer Research to…
In the Journals

Pembrolizumab after radiotherapy appears safe, induces encouraging responses in lung cancer subset

July 15, 2019
Combining radiotherapy and pembrolizumab appeared safe and induced promising responses among patients with advanced non-small cell lung cancer…
Meeting NewsVideo

VIDEO: Early steroids may reduce severe side effects among patients who receive CAR T-cell therapy

July 13, 2019
CHICAGO — Max S. Topp, MD, head of hematology at University Hospital of Wuerzburg, Germany, spoke with HemOnc Today at ASCO Annual…
FDA News

FDA grants orphan drug designation to Imfinzi for small cell lung cancer

July 12, 2019
The FDA granted orphan drug designation to durvalumab for the treatment of small cell lung cancer. Durvalumab (Imfinzi, AstraZeneca) — a human…
In the Journals

Nivolumab shows limited activity in untreated brain metastases from renal cell carcinoma

July 10, 2019
Nivolumab demonstrated limited activity among patients with untreated brain metastases from clear cell renal cell carcinoma who experienced…
Molecular Oncology

Mind the gap: Precision medicine shortcomings in NSCLC

HemOnc Today, July 10, 2019
Howard (Jack) West, MD
This year’s ASCO Annual Meeting included several major successes that should translate to new molecular targets in advanced non-small cell lung…
Cover Story

New treatments, new outcomes for refractory thyroid cancer

HemOnc Today, July 10, 2019
Thyroid cancer diagnoses are increasing rapidly in the United States. But, with an estimated incidence of four cases per million population, thyroid…